VEDBAEK, Denmark, Nov. 14, 2010 (GLOBE NEWSWIRE) -- Exiqon A/S (Copenhagen:EXQ) today published data from a clinical study that stratifies colon cancer patients into groups of high, medium and low chances of survival which may prove useful for optimizing the treatment of each individual cancer patient.
